Inovio Pharmaceuticals
218 hedge funds and large institutions have $693M invested in Inovio Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 88 increasing their positions, 51 reducing their positions, and 45 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 51
19% more capital invested
Capital invested by funds: $581M → $693M (+$112M)
0.24% less ownership
Funds ownership: 3.24% → 2.99% (-0.24%)
4% less funds holding
Funds holding: 227 → 218 (-9)
13% less call options, than puts
Call options by funds: $38.4M | Put options by funds: $44M
13% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 45
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$43.9M |
| 2 |
BlackRock
New York
|
+$35.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.2M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.73M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.6M |
Top Sellers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$8.19M |
| 2 |
Man Group
London,
United Kingdom
|
-$7.06M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7M |
| 4 |
JG
Jefferies Group
New York
|
-$5.49M |
| 5 |
Coatue Management
New York
|
-$4.93M |
INO Hedge Fund Activity: Q1 2021 in Review
218 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2021, worth a combined $693M — up 19% from $581M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of INO and 39 opened new positions — a net loss of 6 holders — while 51 trimmed existing stakes and 88 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $43.9M. The largest seller was Wasatch Advisors, cutting an estimated $8.19M.
- 218 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2021, down from 227 in Q4 2020.
- Funds reported $693M of Inovio Pharmaceuticals stock for Q1 2021, up 19% quarter-over-quarter.
- 39 funds opened new Inovio Pharmaceuticals positions in Q1 2021 and 45 closed out, a net change of -6 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2021 was Avidity Partners Management, an estimated $43.9M added.
- The largest Inovio Pharmaceuticals seller in Q1 2021 was Wasatch Advisors, an estimated $8.19M sold.
Based on aggregated 13F filings for Q1 2021.